Incretin Atlas › Trials › SURMOUNT-5 (head-to-head)
SURMOUNT-5 (head-to-head)
Tirzepatide · obesity
Design
- Molecule(s)
- Tirzepatide
- Population
- obesity
- Official title
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
- Sponsor
- Eli Lilly and Company
- Phase
- 3b
- Registry status
- completed · 2023-04 → 2024-11
- Participants
- 751
- Duration
- 72 weeks
- Registry
- NCT05822830
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| tirzepatide 10/15 mg vs semaglutide 2.4 mg: −13.7 %; treatment discontinuation 21.3 % | obesity | 72 | 751 | −21.6 % | −20.2 % | — | 6.1 | 18.4 | 43.6 | 15.0 | 4.8 | −10.2 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (8)
- tirzepatide 10/15 mg · weight_eff · Figure 2A (efficacy estimand, week 72; text-extracted end-po
−15.4 −21.6
- tirzepatide 10/15 mg · weight_tp · Results, Change in Body Weight; Table 2
The least-squares mean percent change in body weight from baseline to week 72 was −20.2% with tirzepatide (95% confidence interval [CI], −21.4 to −19.1)
- tirzepatide 10/15 mg · ae_dc · Table 3
Discontinuation of the trial treatment because of adverse events 23 (6.1)
- tirzepatide 10/15 mg · nausea · Table 3
Nausea 163 (43.6)
- tirzepatide 10/15 mg · vomiting · Table 3
Vomiting 56 (15.0)
- tirzepatide 10/15 mg · sae · Table 3
Serious adverse events 18 (4.8)
- tirzepatide 10/15 mg · sbp · Results, Change in Waist Circumference and Cardiometabolic R
Systolic blood pressure showed improvements with tirzepatide (least-squares mean change, −10.2 mm Hg; 95% CI, −11.4 to −8.9)
- tirzepatide 10/15 mg · disc_any · Results, Participants (computed 100−81.6)
80.2% completed the 72 weeks of trial treatment (81.6% in the tirzepatide group and 78.7% in the semaglutide group)
Primary sources
- Eli Lilly and Company. A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5). ClinicalTrials.gov identifier NCT05822830. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT05822830
- Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. PMID: 40353578.
How to cite this page
Medical Adviser's Group. Incretin Atlas: SURMOUNT-5 (head-to-head). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-5/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.